pTau-217 (AD-Detect)
Also called Phosphorylated tau 217
A blood biomarker of Alzheimer's-related brain pathology — specifically tau protein phosphorylation associated with amyloid burden.
- Lab price$300.00
- RetestPer physician
What your result means
One of the most significant advances in blood testing in years. Until recently, detecting Alzheimer's pathology required a PET scan or spinal tap. pTau-217 correlates strongly with brain amyloid and can detect changes years before symptoms.
- Standard
- Assay- and lab-specific reference values
- Optimal
- Samewomen carry higher lifetime Alzheimer's risk.
- Standard
- Assay- and lab-specific reference values
- Optimal
- Low/negative.
Not meaningful as a single drawThe value moves too much, or the assay varies too much between labs, for one number to mean anything.
Order it yourself
One test, drawn at a Quest lab near you. The price is the lab’s, from Marek’s own menu.
Code CAMERON takes 10% off. Marek’s checkout adds its one-time blood-draw fee to individual tests and shows the total before you pay.
Order it with APOE Genotyping and Homocysteine (3 tests, one cart)
What moves pTau-217 (AD-Detect)
Alzheimer's disease pathology. Levels rise with amyloid accumulation, often long before cognitive symptoms.
If it’s high: Suggests amyloid pathology — should be interpreted by a physician, ideally with neurology input. It is not a standalone diagnosis.
If it’s low: Reassuring.

The free Before‑You‑Stack Lab Kit
The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.
After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.
Everything else about pTau-217 (AD-Detect)
What your pTau-217 (AD-Detect) result means
Each possible result, and what to do next
What did your pTau-217 result indicate?
- Low / not suggestive
- Argues against significant amyloid pathology. This is a genuinely useful negative, and the main practical value of the test at present.
- Intermediate
- Does not resolve the question. Interpretation depends on the specific assay and on clinical context, and different laboratories are not directly comparable.
- High / suggestive
- Suggests amyloid pathology may be present. That is not the same as dementia — amyloid can be present for many years before symptoms, and some people never develop them.
What to do next. This is a research-grade metric moving into clinical use, and thresholds are assay-specific enough that comparing across labs is unreliable. A concerning result belongs with a neurologist rather than with a supplement plan. The modifiable risk factors remain the highest-value response in every result category: blood pressure, glucose, sleep, hearing, exercise and social engagement.
What can skew the result
2 things can change the reading or the real level
Some change your real level; others only change the reading. Each one says which, and what to do about it.
- Kidney function and BMIPhysiological state
Both affect plasma concentrations of the tau and amyloid markers independently of brain pathology — a real limitation of blood-based neurodegeneration testing.
Do this: Interpret with kidney function in mind, and with a clinician.
A real change — retest once it passes- Sample handlingSample prep
These assays are sensitive to tube type, processing delay and freeze-thaw.
Do this: Use a lab that runs the validated workflow. Do not compare across platforms.
The draw itself skewed it — repeat it
Symptoms it helps explain
1 symptom, and which to test first
Then worth checking for
- Memory concerns, or Alzheimer's runs in my family
Plan of attack
What to do, in this order
- Confirm the number is real
Sample handling. These assays are sensitive to tube type, processing delay and freeze-thaw. Use a lab that runs the validated workflow. Do not compare across platforms.
- Read it with its partner
Best used with physician guidance rather than ordered casually out of curiosity. Draw it alongside: APOE Genotyping, Homocysteine, HbA1c (Hemoglobin A1c).
- Work out which direction is yours
If it's high — Suggests amyloid pathology — should be interpreted by a physician, ideally with neurology input. It is not a standalone diagnosis.
If it's low — Reassuring. - Fix it in order: food, then cause, then everything else
Nutrition. Mediterranean/MIND dietary pattern has the strongest observational support. Control glucose — insulin resistance is a significant risk factor.
Lifestyle. The modifiable levers are substantial and well-evidenced: aerobic exercise, quality sleep (glymphatic clearance), blood pressure control, hearing loss treatment (one of the largest modifiable risk factors per the Lancet Commission), cognitive and social engagement, and avoiding head injury. - Retest
Per physician. Change one thing at a time, or the retest can't tell you which thing worked.
Where the optimal range comes from
Not a range — a result category
Not a range — a result category. Positive or negative, a titre, a genotype. The useful content is what each answer means and what to do next.
- Measured in
- Patients with objective cognitive impairment being seen in specialized memory care. The guideline scope is deliberately narrow.
- Anchored to
- Amyloid status. A blood biomarker test with ≥90% sensitivity and ≥75% specificity may be used to triage; one with ≥90% for both may substitute for amyloid PET.
- Source
- Alzheimer's Association Clinical Practice Guideline on blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease, 2025.
The guideline does not endorse testing cognitively unimpaired or asymptomatic people, and that is the sentence that matters for anyone considering ordering this from a longevity panel. The accuracy figures above were established in people who already had objective cognitive impairment; applied to a population where amyloid pathology is far less common, the same test produces a much higher share of false positives. There is no optimal p-tau217 value, there are assay-specific cut-points, and a positive result in someone without symptoms currently changes no treatment decision while changing a great deal else.
What pTau-217 (AD-Detect) measures
And why people check it
What it tells you
A blood biomarker of Alzheimer's-related brain pathology — specifically tau protein phosphorylation associated with amyloid burden.
Why people check it
One of the most significant advances in blood testing in years. Until recently, detecting Alzheimer's pathology required a PET scan or spinal tap. pTau-217 correlates strongly with brain amyloid and can detect changes years before symptoms.
What pTau-217 (AD-Detect) means next to other markers
1 pattern worth knowing
- APOE ε4 with a normal pTau-217
APOE ε4 carrier · pTau-217 normal · no symptoms
Genuinely reassuring, and worth stating because the genotype alone frightens people. ε4 raises lifetime risk; a normal pTau-217 says the amyloid pathology those risk figures describe is not currently detectable. Many ε4 carriers never develop dementia.
Put the effort into the fourteen modifiable risk factors — hearing, blood pressure, glucose, exercise, sleep, alcohol, social connection. They account for far more than the genotype does, and unlike it they respond.
Panels that carry pTau-217 (AD-Detect)
1 panel, prices with code CAMERON
Read it alongside
Related markers, goals and what moves it in the library
The deep read, with sources
What the pTau-217 (AD-Detect) test actually measures, and the references
What pTau-217 (AD-Detect) actually measures — the analyte, and the assay
What is being measured is one phosphate group on one amino acid. Tau is a microtubule-associated protein carrying dozens of possible phosphorylation sites. Phosphorylation at threonine 217 changes early in amyloid-related pathology, and a small fraction of the modified protein escapes into blood. The test detects that specific modified form, not tau in general.
The concentrations are near the edge of what is measurable. Plasma p-tau217 sits in the low picograms per milliliter, orders of magnitude below its cerebrospinal fluid concentration, which is why the assays are ultrasensitive platforms — single-molecule arrays, high-sensitivity chemiluminescent immunoassays, or immunoprecipitation followed by mass spectrometry — rather than ordinary immunoassays.
Some laboratories report a ratio instead, and the ratio behaves better. Expressing phosphorylated tau217 as a percentage of total tau217 cancels out anything that changes both together. The evidence for that is direct: modeling a fall in filtration rate from an eGFR of 60 to 45 in amyloid-negative participants produced calculated increases of +31% and +55% in two raw p-tau217 assays and only +19% in the percentage form Bornhorst 2025.
Absolute values do not transfer between platforms. Two laboratories measuring the same plasma report different numbers, so every published cut-point belongs to the assay that generated it and to no other.
pTau-217 (AD-Detect): what changes the blood, and what only changes the reading
What changes the p-tau217 in your blood:
- Amyloid pathology in the brain. This is the signal the assay was built for, and in a memory-clinic-like cohort of 202 participants, 114 (56%) were amyloid-PET positive Bornhorst 2025 — which is the prevalence figure the rest of this page keeps coming back to.
- Kidney function, which moves it a great deal. In the same cohort 86 of 202 (43%) had stage 3 to 4 chronic kidney disease, and the effect of reduced filtration on the measured concentration was large enough to require quantifying Bornhorst 2025. Cut-offs for amyloid pathology have since been examined explicitly against kidney function, body mass index and anemia Yun 2026.
- Body mass, through plasma volume. A larger circulating volume dilutes a brain-derived protein arriving at a fixed rate, which lowers the concentration without lowering the pathology Yun 2026.
- Age, which correlates with both the pathology and the filtration rate and therefore contributes twice.
- Amyloid-independent factors in general, which have been separated from amyloid-dependent ones as a distinct source of variability in plasma Alzheimer biomarkers Lee 2024.
What changes only the reading:
- How the sample was handled between the needle and the freezer. Pre-analytical factors have been shown to change the performance of plasma phospho-tau217 Bali 2024, and the delay before processing specifically changes how well plasma p-tau217 and its ratio detect brain amyloidosis Delaby 2025. A protein present at picogram concentrations adsorbs to plastic and degrades in ways a nanogram-level analyte never notices.
- Which tube. Plasma and serum are different matrices for this analyte, and tube material matters at these concentrations Bali 2024.
- Freeze-thaw cycles, each of which costs signal.
- Which platform ran it, and therefore which cut-point applies. The two raw assays in the filtration analysis responded differently to the same physiological change — +31% against +55% Bornhorst 2025.
- Whether you are reading a concentration or a percentage. They are not interchangeable and the percentage is the more stable of the two Bornhorst 2025.
- Hemolysis, which contributes protein and phosphatase activity the assay did not plan for.
Reference interval or decision threshold — which kind of number pTau-217 (AD-Detect) is
These are decision thresholds, tied to a comparator test rather than to a healthy population. A p-tau217 cut-point is chosen by asking which value best separates people who are amyloid-positive on PET or cerebrospinal fluid from people who are not, at a sensitivity and specificity somebody selected. It is not the edge of a normal band.
Most laboratories now use two thresholds and an indeterminate zone between them. Below the lower value the result is treated as unlikely to indicate amyloid pathology, above the upper value as likely, and in between as not answering the question. That middle band exists because a single line forces every borderline person into one of two wrong answers.
The arithmetic that nobody prints is the one that matters most. Predictive value depends on how common the target is in the population tested. In a cohort where 56% were amyloid-positive Bornhorst 2025, a positive result is highly informative. Apply the same threshold to a well 50-year-old with no cognitive symptoms, where the prevalence is a small fraction of that, and the proportion of positive results that are correct falls sharply — not because the assay got worse, but because Bayes' theorem does not care how good the assay is.
Cut-points have already been revised for physiology. Work explicitly adjusting p-tau217 cut-offs for kidney function, body mass index and anemia Yun 2026 exists because a single fixed threshold misclassifies people whose plasma differs for reasons unrelated to their brain.
How you would know your pTau-217 (AD-Detect) was wrong — and when to redraw
The pathology accumulates over years, so the retest interval is measured in years too. Amyloid deposition is a slow process. A meaningful change in plasma p-tau217 driven by pathology takes 12 months or more to appear, which means a repeat at three or six months is measuring the laboratory rather than the brain.
Conditions that must match: the same assay on the same platform, the same tube type and handling protocol, a comparable filtration rate, and comparable body mass Bali 2024 Bornhorst 2025 Yun 2026.
How you would know a change was not about your brain:
- Draw an eGFR or Cystatin-C at the same sitting, every time. A 15-point fall in filtration rate can move a raw p-tau217 by 31% to 55% with no change in pathology Bornhorst 2025. If the biomarker rose and the filtration rate fell, the kidney is the more likely explanation.
- Ask for the percentage form if the platform offers it, since it absorbed less than half the filtration effect the raw assays did Bornhorst 2025.
- Ask how long the sample sat before processing. Preanalytical delay changes detection performance measurably Delaby 2025.
- Check whether body weight changed substantially between the two draws Yun 2026.
- The confirmatory tests are not blood tests. Amyloid PET and cerebrospinal fluid analysis are the comparators the cut-points were built against, and whether either is appropriate is a decision for a clinician, not a consequence of a number.
What pTau-217 (AD-Detect) cannot tell you
It is a marker of amyloid pathology, not of dementia, and the distinction is the whole of the caution on this page. Amyloid pathology is present in people with no symptoms and absent in people with cognitive complaints from other causes. The assay measures a protein modification; it does not measure memory, function or future.
It cannot give a timeline. Nothing in a p-tau217 result states when, whether, or how fast anything would happen. Any reading that supplies one has been supplied by the reader.
It cannot diagnose anything. A blood biomarker sits inside a clinical assessment that includes history, cognitive testing, examination and often imaging. This page explains what the number is and what moves it; it does not tell anybody what they have, and a result of any value should be discussed with a physician before it is acted on.
It cannot be compared with a friend's result, a published mean, or a previous result from a different laboratory, because absolute values are platform-specific Bornhorst 2025.
It cannot be separated from the kidney without measuring the kidney. That is a hard limitation and the reason a filtration estimate belongs on the same requisition Bornhorst 2025 Yun 2026.
The wrong inference readers actually draw is that a positive result in an asymptomatic person is an early diagnosis. In a low-prevalence group most positive results are not confirmed by the comparator test, and the source of variability that produced the positive is as likely to be amyloid-independent as amyloid-dependent Lee 2024.
Sources read for these sections
- Bornhorst JA, et al. Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations. Neurology 2025 · PMID 39823562
- Yun J, et al. Plasma Phosphorylated Tau 217 Cutoffs for Amyloid Pathology and Kidney Function, Body Mass Index, and Anemia. JAMA Neurology 2026 · PMID 41627837
- Bali D, et al. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217. Alzheimer's Research and Therapy 2024 · PMID 38331843
- Delaby C, et al. Impact of preanalytical delay on the performance of plasma Abeta42, Abeta42/40, p-tau217, and p-tau217/Abeta42 in detecting brain amyloidosis in the ALZAN cohort. Alzheimer's and Dementia 2025 · PMID 41166452
- Lee EH, et al. Plasma Alzheimer's disease biomarker variability: Amyloid-independent and amyloid-dependent factors. Alzheimer's and Dementia 2024 · PMID 39535473
pTau-217 (AD-Detect) questions
5 answered
- What is a normal pTau-217 (AD-Detect) level?
- Women: Assay- and lab-specific reference values. Men: Assay- and lab-specific reference values. Ranges vary by laboratory and assay; always compare to the range printed on your own report.
- What is the optimal pTau-217 (AD-Detect) level?
- Women: Same — women carry higher lifetime Alzheimer's risk. Men: Low/negative. Alzheimer's Association Clinical Practice Guideline on blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease, 2025.
- What does an abnormal pTau-217 (AD-Detect) result mean?
- Suggests amyloid pathology — should be interpreted by a physician, ideally with neurology input. It is not a standalone diagnosis.
- How often should I retest pTau-217 (AD-Detect)?
- Per physician.
- How do I test pTau-217 (AD-Detect)?
- Through Marek Diagnostics without a doctor's visit, drawn at a Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically through the links on this page.
Sources: Palmqvist S et al., JAMA 2020 — plasma p-tau217 for Alzheimer's discrimination. Livingston G et al., Lancet 2024 — modifiable dementia risk factors.
The Cognitive Decline & Alzheimer's Risk protocol is a lesson in Skool
This page tells you what the number means and the order to act in. Skool is where it becomes a plan for your situation, read against your own labs.
- The full Cognitive Decline & Alzheimer's Risk protocol, step by step
- Supplement form, timing and how long to run it
- The hormones and compounds that move it, and what to watch
5.0 (15 reviews)1,500+ members

Want it built around you?
Educational and research purposes only. Not medical advice; talk to your clinician about results. Lab ranges vary by assay and laboratory: compare against the range printed on your own report. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer and affiliate disclosure